AstraZeneca Pharma surges on getting nod to import, market Acalabrutinib tablets 100 mg
Astrazeneca Pharma India is currently trading at Rs. 8172.85, up by 117.05 points or 1.45% from its previous closing of Rs. 8291.50 on the BSE.
The scrip opened at Rs. 8298.25 and has touched a high and low of Rs. 8443.00 and Rs. 8002.00 respectively. So far 220 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 10653.05 on 13-Jun-2025 and a 52 week low of Rs. 7630.00 on 06-Apr-2026.
Last one week high and low of the scrip stood at Rs. 8460.00 and Rs. 7630.00 respectively. The current market cap of the company is Rs. 20876.63 crore.
The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 8.26% and 16.74% respectively.
AstraZeneca Pharma India has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import for sale and distribution of Acalabrutinib tablets 100 mg (Brand name: Calquence) for an additional indication.
Through this approval, Acalabrutinib tablets 100 mg in combination with venetoclax with or without obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL) /small lymphocytic lymphoma (SLL).
The receipt of this permission paves way for the marketing of Acalabrutinib tablets 100 mg (Brand name: Calquence) in India for the specified additional indication, subject to the receipt of related statutory approvals, if any.
